TargetMol

Indoximod

Product Code:
 
TAR-T6543
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6543-200mg200mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Indoximod is a methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2, 3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.
CAS:
110117-83-4
Formula:
C12H14N2O2
Molecular Weight:
218.256
Pathway:
Metabolism
Purity:
0.995
SMILES:
Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12
Target:
Indoleamine 2,3-Dioxygenase (IDO)

References

Hou DY, et al. Cancer Res. 2007, 67(2), 792-801. Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer. Molecular Cancer Research. 2019: molcanres. 0239.2019 Metz R, et al. Oncoimmunology. 2012, 1(9), 1460-1468. Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin-resistant lung cancer[J]. Molecular Cancer Research. 2020, 18(1): 105-117. Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer[J]. Molecular Cancer Research. 2019: molcanres. 0239.2019.